aPCC-emicizumab

N/A

Report date: 2026/04/30 20:00:20

Base Information

Drug NameaPCC-emicizumab
Drug Alias NameN/A
ClassificationBiologics > Blood componentsBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionAnti-Factor IXaAnti-Factor XBlood coagulation pathway activation
TargetsCoagulation factor IXCoagulation factor X
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesEmory University
China Registration ClassN/A

Develop Information

Active CompaniesEmory University
Inactive CompaniesN/A
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A